Innovent Biologics set for biggest jump in 5 months on FY revenue growth

China Renaissance Holdings

27/03/2026 05:09

** Shares of Innovent Biologics Inc 1801.HK jump 7.7% to HK$85.55, on course for the biggest one-day pct rise since October 31

** Stock hit its highest level since March 17; sixth-largest pct gainer in the Hang Seng Biotech Index .HSBIO, which rises 3.8%

** The Chinese innovative medicines producer said its 2025 net profit amounted to 813.6 million yuan ($117.69 million), compared with a net loss of 94.6 million yuan in 2024, with revenue up 38.4% y/y at 13.04 billion yuan

** Citi maintains "Buy" on the stock and raises target price to HK$115 from HK$110, saying early stage differentiated candidates, including multiple next generation obesity assets, bispecific and others, could become a long-term growth engine

** YTD, stock up 10.1%

($1 = 6.9132 Chinese yuan renminbi)

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))